Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Net Margin: 2009-2025

Historic Net Margin for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to -86.15%.

  • China Pharma Holdings' Net Margin rose 1546.00% to -86.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -78.72%, marking a year-over-year increase of 685.00%. This contributed to the annual value of -104.58% for FY2024, which is 6067.00% down from last year.
  • Per China Pharma Holdings' latest filing, its Net Margin stood at -86.15% for Q3 2025, which was down 67.25% from -51.51% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Net Margin ranged from a high of -24.28% in Q1 2023 and a low of -155.48% during Q2 2024.
  • Moreover, its 3-year median value for Net Margin was -69.13% (2025), whereas its average is -74.58%.
  • In the last 5 years, China Pharma Holdings' Net Margin tumbled by 10,147bps in 2024 and then soared by 10,397bps in 2025.
  • China Pharma Holdings' Net Margin (Quarterly) stood at -33.94% in 2021, then tumbled by 934bps to -43.28% in 2022, then plummeted by 1,404bps to -57.32% in 2023, then crashed by 5,065bps to -107.98% in 2024, then skyrocketed by 1,546bps to -86.15% in 2025.
  • Its Net Margin stands at -86.15% for Q3 2025, versus -51.51% for Q2 2025 and -69.13% for Q1 2025.